Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (NCT05287451)

🧪 Interventions in This Study

• RIsk-Reducing Salpingectomy (RRS) (OTHER)
• Risk-Reducing Oophorectomy-RRO (OTHER)
• Risk-Reducing Salpingo-Oophorectomy-RRSO (OTHER)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (9 Sites)

• Dana Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic — Rochester, Minnesota
• WU St Louis — St Louis, Missouri
• Mount Sinai Health System — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• University of Pennsylvania — Philadelphia, Pennsylvania
• Lyndon Baines Johnson General — Houston, Texas
• M D Anderson Cancer Center — Houston, Texas
• University of Washington — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (713) 822-4502

Email: rnitecki@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Cancer

• Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
• Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
• Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
• Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
• NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts

Explore by condition: All Ovarian Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.